KURA News and Press, Kura Oncology Inc. From 05/25/24

2024-05-25 10:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-23 17:00:08 ET Bradley Canino from Stifel Nicolaus issued a price target of $28.00 for KURA on 2024-05-23 16:03:00. The adjusted price target was set to $28.00. At the time of the announcement, KURA was trading at $21.43. The overall price target consensus is at ...

– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) --  ...

2024-05-08 08:30:00 ET Growth stocks have resoundingly outperformed value and dividend stocks since the 2008 financial crisis. While this trend is a reversal relative to historical norms, growth stocks are likely to continue to deliver outstanding returns over the long term due to the emerg...

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Confere...

2024-05-07 12:55:52 ET Summary Kura Oncology's stock is likely to maintain a holding pattern in the near term due to lack of major clinical catalysts in 2024. The company's pipeline candidate, ziftomenib, has shown promising results in AML, but there is potential competition in th...

2024-05-04 17:28:08 ET Kura Oncology, Inc. (KURA) Q1 2024 Earnings Conference Call May 2, 2024 04:30 PM ET Company Participants Pete De Spain - EVP, IR Troy Wilson - President & CEO Thomas Doyle - SVP of Finance & Accounting Conference Call Particip...

2024-05-02 17:18:06 ET Gainers: AXT  ( AXTI ) +20% . El Pollo Loco Holdings ( LOCO ) +14% . Tandem Diabetes Care ( TNDM ) +12% . Ardelyx ( ARDX ) +12% . Opendoor Technologies  ( OPEN ) +11% . Losers: Kura Oncolo...

– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data for ziftomenib in NPM1-mutant an...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...